Combining traditional platforming with stunningly beautiful puzzle play, Max: The Curse of Brotherhood will take you on a cinematic fairy-tale adventure.
When Max wishes for his annoying little brother to be whisked away he gets more than he bargained for… Armed with only his trusty Magic Marker, Max must journey to a hostile and unforgiving world to rescue his kidnapped kid brother, Felix.
Draw your way through lantern-lit bogs, ancient temples and lush-green-forests, as you take on Mustacho’s henchmen. Use the marker to overwhelm your enemies, define new pathways and protect you on your quest.
Do not waiver. Unleash the power of the Marker, find your way through a frightening and fantastical world and take down the evil Lord Mustacho.
Release date: 8 June 2017
If you need any additional assets that are not listed, please request them via our contact form.
: The company has supported over 3,800 research sites and enrolled more than 5,400 protocols worldwide, making it a critical player in modern medical advancement. Why Participants Join Other Study Type Study Page - StudyKIK
: The platform is designed to make clinical trials accessible to everyone, covering therapeutic areas ranging from common conditions like asthma and allergies to complex fields like oncology and rare diseases.
: StudyKIK provides a one-stop platform for research sites to manage digital marketing, SMS texting, and global call centers, all aimed at finding qualified patients faster.
Patients with any of the following: * Any type of cancer. * Any type of rare disease. * Asthma. * Atopic Dermatitis. How CRIO and StudyKIK Empower Clinical Research
is a leading global patient recruitment and retention platform that bridges the gap between medical research and the people who need it most. Founded in 2014 and headquartered in Irvine, California, it has transformed the way clinical trials find and engage participants by leveraging a massive network of over 1,000 indication-specific patient communities. Key Features and Impact
: In 2021, StudyKIK was acquired by Syneos Health to bolster their decentralized clinical trial (DCT) capabilities, integrating cutting-edge search and telemedicine tools into the research process.
: The company has supported over 3,800 research sites and enrolled more than 5,400 protocols worldwide, making it a critical player in modern medical advancement. Why Participants Join Other Study Type Study Page - StudyKIK
: The platform is designed to make clinical trials accessible to everyone, covering therapeutic areas ranging from common conditions like asthma and allergies to complex fields like oncology and rare diseases.
: StudyKIK provides a one-stop platform for research sites to manage digital marketing, SMS texting, and global call centers, all aimed at finding qualified patients faster.
Patients with any of the following: * Any type of cancer. * Any type of rare disease. * Asthma. * Atopic Dermatitis. How CRIO and StudyKIK Empower Clinical Research
is a leading global patient recruitment and retention platform that bridges the gap between medical research and the people who need it most. Founded in 2014 and headquartered in Irvine, California, it has transformed the way clinical trials find and engage participants by leveraging a massive network of over 1,000 indication-specific patient communities. Key Features and Impact
: In 2021, StudyKIK was acquired by Syneos Health to bolster their decentralized clinical trial (DCT) capabilities, integrating cutting-edge search and telemedicine tools into the research process.
Publisher: Wired Productions
Developer: Flashbulb Games
Genre: Adventure, Platformer, Puzzle,
Formats: Nintendo Switch, PlayStation 4,
Release Date: PlayStation 4 - 8th November, 2017 / Nintendo Switch - 21st December, 2017
VO: English | Subtitles: English, French, German, Spanish - Spain, Spanish - LA, Portuguese - Brazil. © 2017 Flashbulb ApS. Developed and Published by Flashbulb ApS. Co-published by Wired Productions.
© © 2026 — Deep HarborWired are proud to support the mental health charity for gamers – Safe In Our World
